To test whether prostate cancer cells are dependent on CDC7 activity for growth and evaluate its potential as a therapeutic target, we evaluated the effects of TAK-931, a CDC7-specific inhibitor, on prostate cancer cell growth37,38. This evidence concerns the gene CDC7 and prostate cancer.